Arch Biopartners Inc ACHFF

Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Apr 03, 2024 9:10am

199 Views

Post# 35967233

More Great News

Arch is on a roll snd just keeps pumping out more great news. We get another Canadian site, and it just happens to be the #1 Heart Hospital in Canada and top 10 in the world.

We now have 8 sites on board with one more to be announced for Canada.

You can bet that several sites in the USA have taken notice and it will only be a matter of time before they announce the first site in the USA!

The more sites we have the faster we dose patients. The fact more sites continue to participate in the trial suggest that trial is going well. The more we dose the more we reduce the risk.

<< Previous

Bullboard Posts

Next >>

This gambling tech stock might be the safest bet you’ll make this year